Urothelial Carcinoma

subtype

Identifier: CI-CAN-00004188
Entity page: /cancer/urothelial-carcinoma ↗
Edges: 1,159

Neighbours: 17 genes5 variants19 drugs10 trials
Drawn: 51 of 51 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,147 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Urothelial Carcinoma approved for …APPROVED_FOR10 of 10
← approved for	Pembrolizumabmonoclonal_antibody	supports	FDA ORIG	Urothelial Carcinoma	1	Regulatory	openfda	graph →
← approved for	Nivolumabmonoclonal_antibody	supports	FDA ORIG

Urothelial Carcinoma predicts response to …PREDICTS_RESPONSE_TO7 of 7
in context · predicts response to	High → predicts response to Immunotherapy	sensitivity	B	Urothelial Carcinoma	1	Curated	civic	graph →
in context · predicts response to	FGFR3 N540KSNV → predicts response to Erdafitinib 2 source records aggregated	resistance	C	Urothelial Carcinoma	2	Curated	civic	graph →
in context · predicts response to	FGFR3 N540KSNV → predicts response to Futibatinib	resistance	C	Urothelial Carcinoma	1	Curated	civic	graph →
in context · predicts response to	FGFR3 Y373CSNV → predicts response to Erdafitinib	resistance	C	Urothelial Carcinoma	1	Curated	civic	graph →
in context · predicts response to	FGFR3 Y373CSNV → predicts response to Futibatinib	resistance	C	Urothelial Carcinoma	1	Curated	civic	graph →
in context · predicts response to	PIK3CA E545KSNV → predicts response to Erdafitinib	resistance	C	Urothelial Carcinoma	1	Curated	civic	graph →
in context · predicts response to	FGFR3 S249CSNV → predicts response to Erdafitinib	resistance	C	Urothelial Carcinoma	1	Curated	civic	graph →

Urothelial Carcinoma predicts response to …PREDICTS_RESPONSE_TO7 of 7

in context · predicts response to

High → predicts response to Immunotherapy

sensitivity

Urothelial Carcinoma

Curated

Urothelial Carcinoma associated with …ASSOCIATED_WITH2 of 2
← associated with	FGFR3 2 source records aggregated	supports	C	Urothelial Carcinoma	2	Curated	civic	graph →
← associated with	PIK3CA	supports	C	Urothelial Carcinoma	1	Curated	civic	graph →

Urothelial Carcinoma investigated for …INVESTIGATED_FOR3 of 3
← investigated for	Immunotherapy	supports	B	Urothelial Carcinoma	1	Curated	civic	graph →
← investigated for	Erdafitinibsmall_molecule 2 source records aggregated	supports	C	Urothelial Carcinoma	2	Curated	civic	graph →
← investigated for	Futibatinibsmall_molecule	supports	C	Urothelial Carcinoma	1	Curated	civic	graph →

Urothelial Carcinoma altered in cohorts of …ALTERED_INderived15 of 408show all (up to 200)
← altered in cohorts of	CDH1 27 / 34 cases (79 %) · ssm · blca_plasmacytoid_mskcc_2016	—	—	Bladder Urothelial Carcinoma	1	Observed	cbioportal	graph →
← altered in cohorts of	CDKN2B 267 / 412 cases (65 %) · ssm · TCGA-BLCA	—	—	Bladder Urothelial Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	MTAP 261 / 412 cases (63 %) · ssm · TCGA-BLCA	—	—	Bladder Urothelial Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	UBR5 259 / 412 cases (63 %) · ssm · TCGA-BLCA · largest of 4 cohorts	—	—	Bladder Urothelial Carcinoma	4	Observed	gdc	graph →
← altered in cohorts of	DMRTA1 255 / 412 cases (62 %) · ssm · TCGA-BLCA	—	—	Bladder Urothelial Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	GRHL2 255 / 412 cases (62 %) · ssm · TCGA-BLCA	—	—	Bladder Urothelial Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	COL14A1 253 / 412 cases (61 %) · ssm · TCGA-BLCA · largest of 4 cohorts	—	—	Bladder Urothelial Carcinoma	4	Observed	gdc	graph →
← altered in cohorts of	MYOM2 253 / 412 cases (61 %) · ssm · TCGA-BLCA	—	—	Bladder Urothelial Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	PABPC1 253 / 412 cases (61 %) · ssm · TCGA-BLCA	—	—	Bladder Urothelial Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	TEX15 253 / 412 cases (61 %) · ssm · TCGA-BLCA	—	—	Bladder Urothelial Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	TNFRSF10A 253 / 412 cases (61 %) · ssm · TCGA-BLCA	—	—	Bladder Urothelial Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	ZNF706 253 / 412 cases (61 %) · ssm · TCGA-BLCA	—	—	Bladder Urothelial Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	ADRA1A 252 / 412 cases (61 %) · ssm · TCGA-BLCA	—	—	Bladder Urothelial Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	RIMS2 252 / 412 cases (61 %) · ssm · TCGA-BLCA	—	—	Bladder Urothelial Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	CDCA2 251 / 412 cases (61 %) · ssm · TCGA-BLCA	—	—	Bladder Urothelial Carcinoma	1	Observed	gdc	graph →

Urothelial Carcinoma investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 106show all (up to 200)
→ investigated in trials for	Pembrolizumabmonoclonal_antibody 89 trials (49 active) · roll-up of the cancer and its descendants	—	—	Urothelial Carcinoma	89	Observed	clinicaltrials	graph →
→ investigated in trials for	Gemcitabinesmall molecule 56 trials (33 active) · roll-up of the cancer and its descendants	—	—	Urothelial Carcinoma	56	Observed	clinicaltrials	graph →
→ investigated in trials for	Cisplatinsmall molecule 43 trials (26 active) · roll-up of the cancer and its descendants	—	—	Urothelial Carcinoma	43	Observed	clinicaltrials	graph →
→ investigated in trials for	Nivolumabmonoclonal_antibody 34 trials (17 active) · roll-up of the cancer and its descendants	—	—	Urothelial Carcinoma	34	Observed	clinicaltrials	graph →
→ investigated in trials for	Atezolizumabmonoclonal_antibody 29 trials (7 active) · roll-up of the cancer and its descendants	—	—	Urothelial Carcinoma	29	Observed	clinicaltrials	graph →
→ investigated in trials for	Enfortumab Vedotinadc 29 trials (26 active) · roll-up of the cancer and its descendants	—	—	Urothelial Carcinoma	29	Observed	clinicaltrials	graph →
→ investigated in trials for	Avelumabmonoclonal_antibody 24 trials (8 active) · roll-up of the cancer and its descendants	—	—	Urothelial Carcinoma	24	Observed	clinicaltrials	graph →
→ investigated in trials for	Carboplatinsmall molecule 23 trials (12 active) · roll-up of the cancer and its descendants	—	—	Urothelial Carcinoma	23	Observed	clinicaltrials	graph →
→ investigated in trials for	Docetaxelsmall molecule 20 trials (9 active) · roll-up of the cancer and its descendants	—	—	Urothelial Carcinoma	20	Observed	clinicaltrials	graph →
→ investigated in trials for	Durvalumabmonoclonal antibody 18 trials (12 active) · roll-up of the cancer and its descendants	—	—	Urothelial Carcinoma	18	Observed	clinicaltrials	graph →
→ investigated in trials for	Paclitaxelsmall molecule 14 trials (9 active) · roll-up of the cancer and its descendants	—	—	Urothelial Carcinoma	14	Observed	clinicaltrials	graph →
→ investigated in trials for	Ipilimumabmonoclonal antibody 13 trials (8 active) · roll-up of the cancer and its descendants	—	—	Urothelial Carcinoma	13	Observed	clinicaltrials	graph →
→ investigated in trials for	Mitomycinsmall molecule 12 trials (7 active) · roll-up of the cancer and its descendants	—	—	Urothelial Carcinoma	12	Observed	clinicaltrials	graph →
→ investigated in trials for	Toripalimabmonoclonal antibody 12 trials (11 active) · roll-up of the cancer and its descendants	—	—	Urothelial Carcinoma	12	Observed	clinicaltrials	graph →
→ investigated in trials for	Cabozantinibsmall molecule 11 trials (6 active) · roll-up of the cancer and its descendants	—	—	Urothelial Carcinoma	11	Observed	clinicaltrials	graph →

Urothelial Carcinoma studied in …STUDIED_INderived10 of 623show all (up to 200)
→ studied in	NCT03866382Phase 2 · recruiting Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors · condition mapped ONTOLOGY_EXACT · 623 trials mapped (285 active)	—	—	Invasive Bladder Giant Cell Urothelial Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04628767Phase 2/Phase 3 · recruiting Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer · condition mapped ONTOLOGY_EXACT · 623 trials mapped (285 active)	—	—	Renal Pelvis and Ureter Urothelial Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05874921recruiting uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto · condition mapped ONTOLOGY_EXACT · 623 trials mapped (285 active)	—	—	Urothelial Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05987241Phase 2/Phase 3 · recruiting Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study · condition mapped ONTOLOGY_EXACT · 623 trials mapped (285 active)	—	—	Muscle Invasive Bladder Urothelial Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06524544Phase 3 · recruiting A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer · condition mapped CURATED_BROADER · 623 trials mapped (285 active)	—	—	Urothelial Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07061964Phase 2 · recruiting Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial · condition mapped ONTOLOGY_EXACT · 623 trials mapped (285 active)	—	—	Muscle Invasive Bladder Urothelial Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07671092early Phase 1 · recruiting Imaging Study in Metastatic UC, HR+ and HER2- Breast Cancer, TNBC, and NSCLC · condition mapped CURATED_BROADER · 623 trials mapped (285 active)	—	—	Urothelial Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07705035Phase 1 · recruiting DBC-664 in Adult Patients With Solid Tumors · condition mapped ONTOLOGY_EXACT · 623 trials mapped (285 active)	—	—	Urothelial Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05562830Phase 1/Phase 2 · recruiting A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A) · condition mapped ONTOLOGY_EXACT · 623 trials mapped (285 active)	—	—	Urothelial Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06331299Phase 3 · active not recruiting A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer · condition mapped ONTOLOGY_EXACT · 623 trials mapped (285 active)	—	—	Urothelial Carcinoma	1	Observed	clinicaltrials	graph →

Radial view

Every edge, grouped by relationship

Strongest chains